Skip to content
In stock Sibelium
Neurology

Sibelium

Adults with recurrent migraine or selected vertigo disorders may be prescribed Sibelium, which contains flunarizine. It is a calcium channel blocker used mainly for prevention, not rapid relief…

Guaranteed quality Original product
Delivery: from 4 days Discreet shipping
24/7 Support Always available
Active ingredient: Flunarizine
Select dosage:
Select pack Package Per unit Price
Free Regular Delivery $ 17.58 $ 527.34
Free Express Delivery $ 9.51 $ 1,054.68 $ 570.35 Save 46%
Free Express Delivery $ 7.00 $ 1,582.02 $ 630.19 Save 60%
Free Express Delivery $ 5.56 $ 2,109.36 $ 667.59 Save 68%
Best value Free Express Delivery $ 3.88 $ 3,164.04 $ 697.51 Save 78%
Free Regular Delivery $ 6.95 $ 417.01
Free Regular Delivery $ 4.78 $ 625.52 $ 430.10 Save 31%
Free Regular Delivery $ 3.97 $ 834.02 $ 476.85 Save 43%
Best value Free Regular Delivery $ 2.74 $ 1,251.03 $ 493.68 Save 61%

Free delivery on orders from $ 374.00, free express delivery from $ 561.00

Secure payment methods:
VISA AMEX JCB DISCOVER

Adults with recurrent migraine or selected vertigo disorders may be prescribed Sibelium, which contains flunarizine. It is a calcium channel blocker used mainly for prevention, not rapid relief during an acute migraine.

Product information

It is a calcium channel blocker used mainly for prevention, not rapid relief during an acute migraine. Its clinical role centres on reducing migraine susceptibility and helping selected patients with vestibular symptoms such as vertigo.

Directions for use

Sibelium is available as tablets in different strengths. The strength shown on a product page does not determine the right dose for every person. Dosing differs between strengths and between users, so there is no single amount that suits everyone.

Age, body weight, liver health, migraine pattern, vertigo symptoms, sedation and previous response can affect dose selection. A lower strength may be considered when tolerability is a concern, while a clinician may select another strength for a different clinical situation.

Sibelium Lower-Strength Tablet Presentation

The lower-strength tablet provides a lower-dose option for clinician-directed treatment. It may be considered when gradual treatment selection or greater sensitivity to drowsiness is relevant. The tablet should be taken by mouth according to the prescribed schedule.

Sibelium Higher-Strength Tablet Presentation

The higher strength contains more flunarizine than the lower strength. A strength increase can affect fatigue, drowsiness, appetite and other adverse effects. Older age, liver impairment and a history of depression or movement symptoms may lead to closer review.

The product information for flunarizine supports individualised dosing and monitoring rather than one universal schedule [1].

Administration and Missed Dose Guidance

  • Take Sibelium by mouth at the time prescribed.
  • Swallow the tablet with water unless a prescriber has given different instructions.
  • Do not take extra tablets to compensate for a missed dose.
  • If the next scheduled dose is close, obtain product-specific advice before changing the timing.
  • Do not change between strengths without prescribing guidance.
  • Keep a record of unusual sleepiness, mood changes, tremor or stiffness.
A missed preventive tablet does not need to be “repaid” with a double dose. Extra flunarizine can increase drowsiness and may make the next day less safe for driving.

Ingredients

Sibelium contains flunarizine, a medicine in the calcium channel blocker class. Flunarizine is used in neurology rather than as a routine treatment for high blood pressure. Its clinical role centres on reducing migraine susceptibility and helping selected patients with vestibular symptoms such as vertigo.

Calcium channels are microscopic pathways involved in cell signalling. Flunarizine reduces certain calcium-dependent processes that can contribute to abnormal nerve excitability. This action may lower the tendency for recurrent migraine episodes in suitable patients. The medicine does not usually stop an attack that has already begun. Clinical review helps match this mechanism to the patient’s diagnosis and risk factors.

Flunarizine Pharmacological Action

Migraine involves more than head pain. Changes in nerve signalling, sensory processing and blood-vessel regulation can combine to produce headache, nausea, light sensitivity and sound sensitivity. Flunarizine helps reduce neuronal excitability over time, which is why it is used as a preventive option rather than a rescue tablet.

Medsafe product information describes flunarizine with precautions involving drowsiness, weight gain, depression and movement-related symptoms [1]. These risks influence patient selection and follow-up.

Role in Preventive Treatment

Sibelium may suit patients whose migraines recur often enough to justify daily preventive treatment. The decision depends on headache frequency, disability, previous treatments, other medicines and medical history. A clinician may also consider liver function, age, mood history and symptoms suggesting a movement disorder.

A prevention plan needs time for assessment. A patient may still require a separate acute-migraine treatment for attacks that occur during the preventive course.

Record headache days, pain severity, nausea, light sensitivity and rescue-medicine use. A simple symptom diary gives the prescriber clearer information than memory alone.

How it affects the body

Calcium channels are microscopic pathways involved in cell signalling. Flunarizine reduces certain calcium-dependent processes that can contribute to abnormal nerve excitability. Flunarizine helps reduce neuronal excitability over time.

Therapeutic indications

Sibelium is used mainly for migraine prevention and selected vertigo disorders. These conditions overlap in some symptoms but require different clinical assessments. Dizziness may arise from the inner ear, migraine, blood-pressure changes, medicines, neurological disease or other causes.

Clinical situation Role of Sibelium
Recurrent migraine Preventive treatment that may reduce the frequency or intensity of future episodes
Selected vertigo disorders Symptom management when the suspected cause and clinical assessment support flunarizine use

Migraine Prevention

Sibelium is not generally taken repeatedly during every acute migraine attack. Preventive treatment aims to reduce future episodes across a period of regular use. The expected benefit is judged by changes in headache days, symptom severity and the need for rescue treatment.

Patients often underestimate the value of recording less obvious symptoms. A headache diary can show that attacks are shorter, less disabling or less frequent even when complete relief has not occurred. The World Health Organization recognises migraine as a neurological disorder with substantial effects on daily function [2].

Vertigo Symptom Management

Vertigo describes a spinning or movement sensation, while imbalance and light-headedness may have different causes. Flunarizine may be considered in selected vestibular presentations, but it is not suitable for every type of dizziness.

New weakness, difficulty speaking, fainting, severe headache, chest pain or a sudden change in balance needs urgent medical assessment. These symptoms should not be attributed automatically to an inner-ear problem or treated by self-starting Sibelium.

Common mistakes

Common Patient Mistakes

  • Taking Sibelium as an immediate rescue medicine during every migraine attack.
  • Doubling the next dose after forgetting a tablet.
  • Driving before checking whether the medicine causes drowsiness.
  • Stopping suddenly after improvement without discussing the plan.
  • Ignoring new tremor, stiffness or slowed movement.
  • Failing to report low mood or unusual emotional changes.
  • Assuming that vertigo always has the same cause.
  • Increasing the dose because one episode occurred during treatment.
  • Recording only pain while overlooking nausea, light sensitivity or balance problems.

One practical detail is easy to miss: improved migraine control may take the form of fewer disabling days rather than complete disappearance of every symptom. Another is that fatigue can be mistaken for poor sleep, stress or ageing, so its timing in relation to Sibelium matters.

Write down the tablet time, alertness level and any headache or vertigo symptoms for several days after starting or changing treatment. This can reveal a pattern that is difficult to recall at an appointment.

Reasons not to use it

Sibelium is not suitable for everyone.

Mood and Movement Disorder Precautions

Flunarizine should generally be avoided or used with great caution in people with current depression, previous severe depressive illness or Parkinsonian symptoms, depending on the prescriber’s assessment.

This medicine may be unsuitable when a patient already has unexplained movement symptoms. A clinician may need to review the diagnosis before starting treatment.

Pregnancy, Breastfeeding and Medical History Review

Liver disease may affect treatment decisions because hepatic processing influences exposure to medicines. Severe allergic symptoms, marked confusion or new neurological deficits require urgent medical help rather than routine follow-up.

When this is not for you

NOT for you if you have current depression, Parkinsonian symptoms or sedation that makes normal activities unsafe without clinician review. The main concern is not only the migraine diagnosis but also the person’s neurological and psychiatric history, current medicines and ability to tolerate sedation.

Sibelium can impair alertness. Tell the prescriber about sleeping tablets, opioid analgesics, sedating antihistamines, anti-anxiety medicines and other drugs that cause drowsiness. A complete medicines list helps identify additive effects.

Pregnancy and breastfeeding require individual assessment because treatment decisions depend on the balance between migraine control, available alternatives and potential infant exposure. Do not start, stop or continue Sibelium during pregnancy without discussing the situation with a prescriber or pharmacist.

Unwanted effects

Flunarizine can cause fatigue, drowsiness, increased appetite, weight gain and gastrointestinal discomfort. Hair loss has also been reported. The likelihood and severity vary between patients, and not every listed effect occurs frequently.

Fatigue and Drowsiness

Fatigue may appear as reduced energy, sleepiness, slower concentration or difficulty staying alert. This matters during the first days of treatment and after a dose change. Do not drive, cycle on busy roads or operate machinery if you feel drowsy or mentally slowed.

Alcohol, sleeping tablets, opioid pain medicines, sedating antihistamines and other central nervous system depressants may worsen impaired alertness. A person may feel “used to” the medicine while still having slower reaction times.

Test your alertness on a quiet day before returning to driving or machinery work. Feeling awake at home does not prove that reaction speed is unchanged.

Hair Loss and Weight Changes

Hair loss and increased appetite can be distressing, especially when they develop gradually. Do not stop treatment or alter the dose without a planned review. A clinician may assess timing, other medicines, thyroid health, nutritional factors and alternative explanations before deciding what to do.

Weight change can result from increased appetite, reduced activity during fatigue or other health factors. Tracking weight and appetite weekly can make a later review more useful than relying on impressions.

Serious or Persistent Reactions

Prompt medical review is needed for:

  • Persistent low mood, loss of interest or thoughts of self-harm.
  • New tremor, stiffness, slowed movement or unusual restlessness.
  • Marked confusion or severe deterioration in alertness.
  • Repeated falls or impaired balance.
  • Severe allergic symptoms, facial swelling or breathing difficulty.
  • New neurological deficits, such as weakness or trouble speaking.

Older adults may be more vulnerable to sedation, falls and movement-related adverse effects.

Comparison

Sibelium should not be exchanged automatically with another medicine. The active ingredient, treatment goal, adverse-effect profile and patient’s medical history all matter.

Treatment approach Main clinical role and cautions
Flunarizine Migraine prevention and selected vertigo management; monitor sedation, weight change, mood and movement symptoms
Cinnarizine Used in selected vestibular or motion-related conditions; sedation and movement-related precautions may matter
Betahistine Used in selected vestibular disorders; suitability depends on the diagnosis and patient history
Propranolol May be considered for migraine prevention; caution is needed with asthma, low blood pressure or a slow heart rate

Cinnarizine is the active ingredient in Stugeron, while betahistine is the active ingredient in Vertin OD. Propranolol is the active ingredient associated with Ciplar LA. These names describe different medicines and should not be treated as interchangeable versions of Sibelium.

Propranolol may be useful for some patients with migraine prevention needs, though asthma, bradycardia and hypotension can limit its use. Betahistine has a different clinical role and should not be selected simply because dizziness is present. Cinnarizine may also cause sedation, so changing from one medicine to another does not automatically remove alertness concerns.

What doctors say

In clinical practice, doctors usually frame Sibelium as a preventive option for carefully selected patients rather than a universal migraine tablet. The expected benefit is measured against sedation, weight change, mood effects and movement symptoms.

A clinician will often ask how many migraine days occur each month, how disabling they are and which acute treatments have been tried. For vertigo, the examination and suspected cause matter just as much as the symptom itself.

The New Zealand Medicines and Medical Devices Safety Authority, Medsafe, provides medicine-safety information for medicines used in New Zealand. NICE and the American Headache Society also publish migraine-management guidance, while local product information governs flunarizine prescribing. Reporting a new tremor, stiffness, persistent depression or severe sleepiness early allows treatment decisions to be made before the problem becomes harder to manage.

Doctors also consider whether the patient can safely perform normal activities. A treatment that reduces headache frequency but causes unsafe sedation may require a different dose or another preventive approach.

What customers often ask

Is Sibelium suitable during pregnancy or breastfeeding?

Pregnancy and breastfeeding require an individual review because flunarizine exposure and migraine severity must be considered together. Medsafe product information from 2021 identifies pregnancy and lactation as situations requiring clinical assessment rather than routine self-treatment [1]. Medsafe guidance in New Zealand also supports discussing medicine use during pregnancy and breastfeeding with a qualified prescriber or pharmacist. Do not change treatment solely because migraine symptoms have improved or worsened.

Can Sibelium affect driving, concentration or machinery work?

Yes. Drowsiness, fatigue and slower concentration can occur with flunarizine, especially after treatment starts or the strength changes. Medsafe product information from 2021 advises caution with activities requiring alertness when these effects are present. Avoid driving or machinery work until you know how Sibelium affects you, and take extra care if alcohol or another sedating medicine is involved.

How long does one dose of Sibelium keep working?

Sibelium is intended for preventive treatment, so its value is assessed across repeated dosing rather than as rapid relief from one acute migraine. Flunarizine has a long-lasting pharmacological effect, and symptoms may not change immediately after an individual tablet. Medsafe product information from 2021 describes flunarizine’s prolonged presence in the body, which is one reason clinicians use scheduled treatment rather than repeated rescue doses. Follow the prescribed timing and do not take extra tablets during an attack.

How long does a course last, and is long-term use acceptable?

The course length depends on migraine frequency, response, adverse effects and the reason for treatment. Some patients need a defined trial followed by review, while others require longer monitoring when the benefit remains clear. WHO migraine guidance published in 2023 supports regular reassessment of preventive treatment and disability rather than indefinite continuation without review. Long-term use may be considered in selected patients, with attention to mood, movement symptoms, weight and sedation.

Can people under 18 use Sibelium?

Use in children and adolescents requires specialist or prescriber assessment because the diagnosis, dose selection and safety profile differ from adult treatment. Medsafe product information from 2021 does not make adult dosing a suitable automatic guide for younger patients. A clinician may first assess migraine features, neurological findings, growth, other medicines and the possibility of an alternative diagnosis. Do not give an adult Sibelium tablet to a person under 18 without specific prescribing instructions.

Do you offer anonymous delivery?

Your order will be securely packed and shipped within 24 hours. This is exactly what your package will look like (images of an actual item sent). It has the size and look of a regular private letter (24x11x0.7 cm) and its contents cannot be seen.

Comparison

How the medicines for Neurology compare

How Buyers Rate Sibelium

Based on 4 reviews

Helen, 42 Verified
Rating: 3.5 out of 5

My migraine days became less disruptive, and I needed fewer rescue tablets. The first week brought noticeable tiredness, so I stopped driving after work until I knew how I reacted.

Rotorua Several weeks 13 Nov 2026
Amanda, 58 Verified
Rating: 3.5 out of 5

The spinning episodes became less frequent after a period of regular treatment. I also felt hungrier and gained some weight, so my prescriber reviewed whether the benefit still justified continuing.

Whanganui A period of regular treatment 17 Oct 2026
Lisa, 27 Verified
Rating: 3.5 out of 5

I expected it to stop an attack straight away, which was the wrong expectation. The diary showed fewer headache days after several weeks, although fatigue made early-morning study difficult.

Gisborne Several weeks 1 Nov 2026
Susan V., 63 Verified
Rating: 2 out of 5

The headaches seemed quieter, but I noticed stiffness and a tremor. I contacted my prescriber instead of changing the dose myself, and we arranged a different plan.

Ashburton 22 Oct 2026

Sources

  1. Medsafe (2021). Sibelium (flunarizine) data sheet
  2. World Health Organization (2023). Headache disorders
Get our free app Shop faster and track your orders 3.9 · 370 reviews Install